Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD2014 plus weekly paclitaxel in relapsed/refractory squamous NSCLC (Phase 2a, single-arm)
2015-000159-26Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Apr 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of vistusertib in Pulmonary squamous cell carcinoma, sponsored by AstraZeneca. Primary endpoint: Objective response rate. Started Apr 2015; status: completed.
02
Drugs
vistusertib
03
Conditions
Pulmonary squamous cell carcinoma
Beyond the preview
Go deeper on 2015-000159-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-000159-26.